Schizophrenia
Conditions
Interventions
Experimental group:Regular treatment, additional use Sweet Dream Oral Liquid 10mL po bid
Control group:Regular treatment
Sponsors
Wuhan Mental Health Center
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Meeting the diagnostic criteria for schizophrenia in the Chinese Classification and Diagnostic Standard of Mental Disorders, 3rd Edition (Classification of Mental Disorders); 2. A total score of >= 60 on the Positive and Negative Symptom Scale (PANSS); 3. Inpatient aged 18-60 years, male; 4. Treatment with maintenance doses of atypical antipsychotics for >= 12 weeks and no endocrine-affecting drugs, such as prednisone; 5. Subjects need to have the ability to understand and communicate effectively with the investigator to complete study-related assessment components; 6. The patient's family has signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those with a family history of obesity; 2. Renal failure; abnormal thyroid function; ovarian lesions; pituitary tumours; 3. Persons with a history of psychoactive drug dependence; 4. Persons with a positive urine drug screen and alcohol or drug abuse/dependence within the past year; 5. Patients who have had an ineffective treatment with Sweet Dream Oral Solution within 2 months prior to assessment; 6. Patients with psychiatric disorders due to organic somatic diseases; 7. Patients who are uncooperative, unable to communicate or deemed unsuitable by the investigator to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prolactin;Testosterone;Complete Blood Count; | — |
Secondary
| Measure | Time frame |
|---|---|
| Brain-derived neurotrophic factor;Interleukin-6;C-reactive protein; | — |
Countries
China
Contacts
Public ContactMaosheng Fang
Wuhan Mental Health Center
Outcome results
None listed